PathAI logo


Immunohistochemistry (IHC) · Oncology

Within the hemopoietic system, CD138 is mainly confined to late stages of B-cell differentiation. CD138 expression is reduced during malignant transformation of various epithelia, and CD138 is rapidly shed by myeloma cells entering into apoptosis, making CD138 a marker of viable myeloma cells. This antibody is useful for the identification of malignancies involving terminally differentiated plasma cells, and CD138 is associated with multiple myeloma. Anti-CD138 may also be useful for the subclassification of diffuse large B-cell lymphomas.